Salix Pharmaceuticals Reports 2Q2012 Results

The Company will host a conference call at 5:00 p.m. ET, on Wednesday, August 8, 2012. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at www.salix.com. A replay of the web cast will be available at the same location. The telephone numbers to access the live conference call are [phone] (U.S. and Canada) or [phone] (international.) The telephone numbers to access the replay of the call are [phone] or [phone] (U.S. and Canada) or [phone] (international). The access code for the replay is 95495680.

About Salix

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN ^® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP ^® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP ^® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO ^® (mesalamine) extended-release capsules 0.375 g, METOZOLV ^® ODT (metoclopramide HCl), RELISTOR ^® (methylnaltrexone bromide) Subcutaneous Injection, SOLESTA ^®, DEFLUX ^®, PEPCID ^® (famotidine) for Oral Suspension, Oral Suspension DIURIL ^® (Chlorothiazide), AZASAN ^® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC ^® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC ^® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT ^® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT ^® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Crofelemer, budesonide foam, RELISTOR ^® , LUMACAN ^® and rifaximin for additional indications are under development.

For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP and METOZOLV, please visit www.salix.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.

« First ‹ Previous 1 2 3 4 5 6 7 8 Next › Last »